TITLE

Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices

AUTHOR(S)
Lexchin, Joel
PUB. DATE
April 2006
SOURCE
CMAJ: Canadian Medical Association Journal;4/11/2006, Vol. 174 Issue 8, p1120
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article comments on the competition in prices of drugs in Canada and the U.S. in 2006. Because of the differences between the U.S. and Canadian markets, drug manufacturers in Canada may adopt pricing strategies different from those used in the U.S. The impact of this arrangement in the pharmaceutical industry is emphasized. In addition, this article addresses the observation that the lack of price competition was evident even for drugs used to treat acute or chronic conditions.
ACCESSION #
20879493

 

Related Articles

  • Pharmaceutical industry battling losses internally and in court. Wylot, Robert // Warsaw Business Journal;4/22/2002, Vol. 8 Issue 16, p3 

    Reports the changes in drug regulatory prices in Poland. Lack of transition period; Decrease in the prices of foreign-made drugs; Authority in suing the government of companies affected by the lack of transition period.

  • Surging drug costs will be hard to tame. Goldblatt // Business News New Jersey;11/29/99, Vol. 12 Issue 44, p24 

    Reports on the increasing of drugs and other pharmaceutical products in the United States. Reasons for the said increase; Estimated increase in consumer spending on prescription drugs; Actions taken by concerned entities to address the problem.

  • Prescription Benefits. Goldblatt, Dan // Business News New Jersey;6/26/2001, Vol. 14 Issue 26, p10 

    Focuses on the challenges faced by the United States pharmaceutical industry. Pricing pressures; Need of maintaining an unrestricted profit margin to pay for the research and development of future drug breakthroughs; Desire of insurers for big discounts on prescription drugs.

  • Settlement doesn't solve pricing practices inequity.  // Drug Store News;2/12/96, Vol. 18 Issue 3, p29 

    Reports that the settlement proposed by pharmaceutical manufacturers to resolve the class-action discriminatory pricing suit filed by independent pharmacists will not solve pricing practice inequity, according to the National Association of Chain Drug Stores president Ronald L. Ziegler. Terms of...

  • No relief in sight for rising drug costs. Connors, Kristine // Managed Healthcare Executive;Jul/Aug2001, Vol. 11 Issue 7, p13 

    Reports on the continuous rise in pharmaceutical prices in the United States. Factors attributing to such industry trend; Reaction of American consumers to the continuous rise in drug prices in the country; Expectations that drug benefit packages in the country might begin to change during the...

  • Prescription Blackmail. Buell, John // Humanist;Sep/Oct99, Vol. 59 Issue 5, p42 

    Focuses on the regulation of the prices of drugs in the United States (US). Legal monopoly of pharmaceutical corporations; Activities to which pharmaceutical companies spend their income on; Policies of US President Bill Clinton on prescription drugs.

  • News update.  // Materials Management in Health Care;Apr99, Vol. 8 Issue 4, p11 

    Reports on the increase in overall prices for medical care commodities in February 1999, according to the United States Labor Department's Consumer Price Index report. Increase in prescription drug prices; Decline of over-the-counter drug prices.

  • States battle for drug discounts. Wechsler, Jill // Managed Healthcare;Dec2000, Vol. 10 Issue 12, p15 

    Reveals that United States consumers are taking the campaign for drug price relief to state legislatures. Lack of congressional response to the problem; Maine's adoption of a program that pressures pharmaceutical companies to negotiate lower prices with state agencies; Vermont's extension of...

  • Drug hikes.  // Budapest Business Journal;1/27/2003, Vol. 11 Issue 7, p1 

    Reports on the price increases for 5,283 drugs on the Hungarian state subsidy list which took effect on February 1, 2003. Average price increase of the drugs; Criticism of the price hike from the Hungarian pharmaceutical industry; Additions to the list of subsidized drugs.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics